Literature DB >> 1489229

Thrombolysis with low dose tissue plasminogen activator.

E Doyle1, J Britto, J Freeman, F Munro, N S Morton.   

Abstract

Two cases of vena caval thrombosis in infants were successfully treated with low dose (0.01-0.05 mg/kg/hour) local infusions of tissue plasminogen activator after conventional anticoagulant treatment had been unsuccessful. This approach is useful for clots associated with indwelling intravascular catheters, and a low dose infusion of tissue plasminogen activator as a regional application is recommended to achieve clot lysis with minimal systemic effects.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1489229      PMCID： PMC1793968          DOI： 10.1136/adc.67.12.1483

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  6 in total

1.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

2.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.

Authors:  H S Mueller; A K Rao; S A Forman
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

Review 3.  Thrombolytic therapy: current status (2).

Authors:  V J Marder; S Sherry
Journal:  N Engl J Med       Date:  1988-06-16       Impact factor: 91.245

4.  Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.

Authors:  B J Anderson; S R Keeley; N D Johnson
Journal:  Anaesth Intensive Care       Date:  1991-02       Impact factor: 1.669

5.  Tissue plasminogen activator for the treatment of thromboembolism in infants and children.

Authors:  M Levy; L N Benson; P E Burrows; Y Bentur; D K Strong; J Smith; D Johnson; S Jacobson; G Koren
Journal:  J Pediatr       Date:  1991-03       Impact factor: 4.406

6.  Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.

Authors:  C D Naylor; P W Armstrong
Journal:  CMAJ       Date:  1989-06-01       Impact factor: 8.262
  6 in total
  5 in total

Review 1.  Pulmonary embolism in parenteral nutrition.

Authors:  C M Dollery
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

Review 2.  Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature.

Authors:  J Hartmann; A Hussein; E Trowitzsch; J Becker; K H Hennecke
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-07       Impact factor: 5.747

Review 3.  Management of preterm infants with intracardiac thrombi: use of thrombolytic agents.

Authors:  P C Rimensberger; J R Humbert; M Beghetti
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children.

Authors:  W Zenz; W Muntean; A Beitzke; G Zobel; M Riccabona; A Gamillscheg
Journal:  Br Heart J       Date:  1993-10

Review 5.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.